Corcept Therapeutics (CORT) Profit After Tax (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Profit After Tax data on file, last reported at -$31.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 251.86% year-over-year to -$31.2 million; the trailing twelve-month figure through Mar 2026 stood at $47.6 million (down 64.39% YoY), and the FY2025 full-year result was $99.7 million, down 28.68% from the prior year.
• Profit After Tax declined to -$31.2 million in Q1 2026, from $24.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $47.2 million in Q3 2024 to a low of -$31.2 million in Q1 2026.
• A 5-year average of $24.5 million and a median of $27.5 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax jumped 88.37% in 2023 and sank 251.86% in 2026, its largest moves.
• Tracing CORT's Profit After Tax over 5 years: stood at $16.5 million in 2022, then jumped by 88.37% to $31.1 million in 2023, then dropped by 2.42% to $30.4 million in 2024, then decreased by 20.08% to $24.3 million in 2025, then sank by 228.47% to -$31.2 million in 2026.
• Business Quant data shows CORT's Profit After Tax at -$31.2 million in Q1 2026, $24.3 million in Q4 2025, and $19.4 million in Q3 2025.